Evidence map›Paper›PMID 42033516›Full record

ArticleJournal of gastrointestinal cancer2026

CD74

Tianwei Xu, Anwei Xue, Yueda Chen, Chao Lin, Dansong Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tianwei Xu *Department of Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Anwei Xue *Department of General Surgery, Shanghai Geriatric Medical Center, Shanghai, China.
Yueda Chen *Department of General Surgery, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China.
Chao LinDepartment of Acute Care Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. lin.chao@zs-hospital.sh.cn.
Dansong WangDepartment of Acute Care Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. wang.dansong@zs-hospital.sh.cn.

Funding

National Natural Science Foundation of China 82303966
6 · The paper itself

Abstract

backgroundCD74 upregulation on tumour-associated macrophages (TAMs) limits phagocytosis. However, the effect of CD74+TAMs on adaptive immunity in gastric cancer remains obscure.

methodsThe study enrolled four cohorts, consisting of two tumor microarrays of patients with gastric cancer from Zhongshan Hospital (448 undergoing curative surgeries, 46 treated with ICI plus palliative chemotherapy), 269 transcriptional data from The Cancer Genome Atlas, and 43 transcriptional data from Korean patients treated with pembrolizumab. CD74+TAMs gene signature was directly acquired from public datasets, and we also detected CD74+TAMs infiltration on tumor microarray by immunofluorescence. Finally, the associations of CD74+TAMs with clinical outcomes and genomic features were analyzed. In vitro culture of fresh tumor tissue was performed to evaluate the potential therapeutic effect of blocking PD-1 in gastric cancer.

resultsIncreased level of CD74+TAMs indicates poor clinical outcome in patients with resectable gastric cancer. In advanced gastric cancer, high CD74+TAMs infiltration was associated with better response to ICI. CD74+TAMs fostered an immunosuppressive microenvironment by expressing PD-L1. Blockade of PD-1 increases anti-tumor immunity in CD74+TAMshigh tumours.

conclusionsCD74+TAMs infiltration is a prognostic factor for prognosis in patients with resectable gastric cancer and a predictor for response to ICI in patients with advanced gastric cancer. CD74+TAMs contribute to the immunosuppressive microenvironment by expressing PD-L1 in gastric cancer. CD74+TAMs infiltration is a potential predictor for response to ICI in gastric cancer.

Indexed as

Antigens, Differentiation, B-LymphocyteB7-H1 AntigenStomach NeoplasmsTumor-Associated MacrophagesTumor EscapeFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsMaleMiddle AgedPrognosisTumor MicroenvironmentAntigens, Differentiation, B-LymphocyteB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsCD74Gastric cancerImmune escapeMacrophagesTherapeutic response

Identifiers

PMID42033516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.